Explore how pharmaceutical manufacturers can address TFA-containing wastewater generated through peptide synthesis and purification. This case study breaks down why GLP-1 and peptide manufacturing are increasing demand for on-site PFAS destruction, demonstrates how HALT destroys TFA in complex high-salt and high-TDS waste streams, and highlights the benefits of reducing reliance on off-site disposal.
To access the full case study, fill out the form below.
